热门资讯> 正文
Guardant Health以高达1.5亿美元收购以色列医疗科技MetaSight
2026-02-20 23:41
- Guardant Health (GH) has acquired MetaSight Diagnostics for $59M upfront and up to $90M in milestone payments.
- The Israeli startup is known for developing early cancer and liver fibrosis detection tests that use liquid biopsy technology.
- Guardant will maintain MetaSight's team in Rehovot.
- MetaSight was founded in 2020 as a collaboration between between Israeli healthtech and life sciences investment fund aMoon and Computer Science and Biology Professor Tomer Shlomi at the Technion.
More on Guardant Health
- Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
- Guardant Health: Look For Explosive Revenue Growth Ahead
- Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth
- Guardant Health outlines 27%–30% revenue growth for 2026 while expanding Shield and oncology portfolio
- Guardant Health guides Q4 and FY25 revenue above consensus
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
